Name Surname: TAYFUN EYİLETEN
Güven Hospital
Department: Internal Medicine
2. Department: Nephrology
Academic Title: Professor
Title: Head of Department
CV: Download
CV
Eyileten T, CV 1
Prof. Tayfun EYİLETEN, M.D.
CURRICULUM VITAE
Name : Tayfun
Surname : Eyileten
Title : Professor
Date of Birth : November 28, 1965
Nationality : R.T.
Marital status : Married
EDUCATION
Associate Professor : Nephrology Division, Gülhane School of Medicine
Date : December 2010 - June 2017
Fellow : Transplantation Unit of Hospital of University of Pennsylvania (UPENN), Philadelphia USA.
Date : December 2010 – December 2011
Assistant Professor : Nephrology Division, Gülhane School of Medicine
Date : September 2006 - December 2010
Fellow : Nephrology Division, Gülhane School of Medicine
Date : July 2003 - August 2006
Internist : Internal Medicine Department, Mevki Hospital, Ankara
Date : November 1999 – July 2003
Residency Education : Internal Medicine Department, Gülhane School of Medicine
Date : September 1995 – November 1999
Medical Practitioner : Turkish Armed Forces
Date : May 1991 – September 1995
Eyileten T, CV 2
School of Medicine: Gülhane School of Medicine
Date: 1983 - 1990.
COURSES
Course : 14th Budapest Nephrology School
Duration : 6 day(s).
Date : 25/08/2007 – 30/08/2007
Address : Semmervils University, Budapest, Hungary
Course : Board Review Course in Nephrology
Duration : 5 day(s)
Date : May 2008
Address : Harvard Medical School, Boston, USA
Course : Board Review Course in Nephrology
Duration : 5 day(s)
Date : May 2010
Address : Harvard Medical School, Boston, USA
Course : Transplantation Course
Duration : 5 day(s)
Date : August 2010
Address : Barcelona Clinic SPAIN.
Course : Transplantation Course
Duration : 2 Day(s)
Date : October 2011
Address : 2011 ATC Congress in Philadelphia, USA
Course : Transplantation Course
Duration : 1 day(s). Date: March 2015
Address : 2015 ASN Congress in Atlanta, USA
Eyileten T, CV 3
RESEARCH TITLES : Hypertension, Kidney Transplant Surgery, Intensive Care.
H(Hirsch) Index : 28. Articles listed in
SCI-Expanded index : 69
Faculty member in Gülhane School of Medicine, 2006-2017 (2nd, 3rd and 4th Grade)
School of Medicine (3rd Grade) and Health Sciences Institute of Near East University, 2014-2018
A. ARTICLES listed in the SCI index
Eyileten T, CV 4
1) Mas MR, Saglamkaya U, Kubar A, Colakoglu M, Ateskan U, Erdem H, Nalbant S, Eyileten T, Comert B, Unal T, Kocabalkan F.: Hepatitis G virus infection among patients undergoing hemodialysis. Nephron. 1998 Oct;80(2):247-8.
2) Uçkaya G, Ozata M, Sonmez A, Kinalp C, Eyileten T, Bingol N, Koc B, Kocabalkan F, Ozdemir IC.: Plasma leptin levels strongly correlate with plasma renin activity in patients with essential hypertension. Hormon Metab Resc. 1999 Jul;31(7):435-8.
3) Uckaya G, Ozata M, Sonmez A, Kinalp C, Eyileten T, Bingol N, Koc B, Kocabalkan F, Ozdemir IC.: Is leptin associated with hypertensive retinopathy? J Clin Endocrinol Metab.2000 Feb;85(2):683-7.
4) Sonmez A, Kisa U, Uckaya G, Eyileten T, Comert B, Koc B, Kocabalkan F, Ozata M.: Effects of losartan treatment on T-cell activities and plasma leptin concentrations in primary hypertension. J Renin Angiotensin Aldosteron Syst;2(2):112-6.
5) Yenicesu M, Yilmaz MI, Caglar K, Sonmez A, Eyileten T, Acikel C, Kilic S, Bingol N, Bingol S, Vural A.: Blockade of the renin-angiotensin system increases plasma adiponectin levels in type-2 diabetic patients with proteinuria. Nephron Clin Pract. 2005;99(4):c115-21
6) Yilmaz MI, Sonmez A, Caglar K, Gok DE, Eyileten T, Yenicesu M, Acikel C, Bingol N, Kilic S, Oguz Y, Vural A.: Peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist increases plasma adiponectin levels in type 2 diabetic patients with proteinuria. Endocrine. 2004 Dec;25(3):207-14
7) Vural A, Yilmaz MI, Caglar K, Aydin A, Sonmez A, Eyileten T, Acikel C, Gulec B, Kozak O, Oner K.: Assessment of oxidative stress in the early posttransplant period: comparison of cyclosporine A and tacrolimus-based regimens. Am J Nephrol. 2005 May-Jun;25(3):250-5.
8) Sonmez A, Dogru T, Yilmaz MI, Ocal R, Ozgurtas T, Kilic S, Eyileten T, Tasci I, Erbil K, Kocar IH.: Soluble CD40 ligand levels in patients with hypertension. Clin Exp Hypertens. 2005 Nov;27(8):629-34
9) Yenicesu M, Yilmaz MI, Caglar K, Sonmez A, Eyileten T, Kir T, Acikel C, Bingol N, Oguz Y, Ikizler TA, Vural A.: Adiponectin level is reduced and inversely correlated with the degree of proteinuria in type 2 diabetic patients. Clin Nephrol. 2005 Jul;64(1):12-9.
10) Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, Aydin A, Eyileten T, Ozcan O, Acikel C, Tasar M, Genctoy G, Erbil K, Vural A, Zoccali C.: The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis. 2006 Jan;47(1):42-50.
11) Yilmaz MI, Saglam M, Caglar K, Cakir E, Ozgurtas T, Sonmez A, Eyileten T, Yenicesu M, Acikel C, Oguz Y, Ozcan O, Bozlar U, Erbil K, Aslan I, Vural A.: Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. Transplantation. 2005 Dec 27;80(12):1660-6
Eyileten T, CV 5
12) Yilmaz MI, Korkmaz A, Kaya A, Sonmez A, Caglar K, Topal T, Eyileten T, Yenicesu M, Acikel C, Oter S, Yaman H, Aktug H, Oguz Y, Vural A, Ikizler TA.: Hyperbaric oxygen treatment augments the efficacy of a losartan regime in an experimental nephrotic syndrome model. Nephron Exp Nephrol. 2006;104(1):e15-22.
13) Dogru T, Sonmez A, Tasci I, Yilmaz MI, Kilic S, Ozgurtas T, Eyileten T, Erbil MK, Kocar IH.: Plasma adiponectin and insulin resistance in new onset hypertension. Endocrine 2006 Jun;29(3):405-8.
14) Sonmez A, Kisa U, Uckaya G, Eyileten T, Kinalp C, Yilmaz MI, Dogru T, Turan M, Kocar IH.: Asymptomatic kindred of patients with coronary events have increased peripheral T-cell activities. Heart Vessels 2006 Jul;21(4):242-6.
15) Caglar K, Yilmaz MI, Sonmez A, Cakir E, Kaya A, Acikel C, Eyileten T, Yenicesu M, Oguz Y, Bilgi C, Oktenli C, Vural A, Zoccali C.: ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int. 2006 Aug;70(4):781-7.
16) Caglar K, Yilmaz MI, Saglam M, Cakir E, Kilic S, Eyileten T, Sonmez A, Oguz Y, Oner K, Ors F, Vural A, Yenicesu M.: Endothelial dysfunction and fetuin A levels before and after kidney transplantation. Transplantation. 2007 Feb 27;83(4):392-7.
17) Yilmaz MI, Sonmez A, Çaglar K, Celik T, Yenicesu M, Eyileten T, Acikel C, Oguz Y, Yavuz I, Vural A.: Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton). 2007 Apr;12(2):147-53.
18) Yilmaz MI, Saglam M, Sonmez A, Caglar K, Cakir E, Kurt Y, Eyileten T, Tasar M, Acikel C, Oguz Y, Vural A, Yenicesu M.: Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan. Blood Purif. 2007;25(4):327-35
19 ) Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, EyiletenT, SonmezA, Cakir E, YenicesuM, Lindholm B, Stenvinkel P and Axelsson J. Serum Visfatin Concentration And Endothelial Dysfunction in Chronic Kidney Disease. Nephrol Dial Transplant. 2007 23(3):959-65
20) Caglar K, Yilmaz MI, SaglamM, CakirE, AcikelC, Eyileten T, Yenicesu M, Oguz Y, Vural A, Carrero JJ, Axelsson J, Lindholm B, Stenvinkel P.: Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol. 2008 Jan;3(1):61-8.
21) Sonmez A, Yilmaz MI, Korkmaz A, Topal T, Caglar K, Kaya A, Eyileten T, Yenicesu M, Oguz Y, Basal S, Ipcioglu OM, Vural A.: Hyperbaric oxygen treatment augments the efficacy of cilazapril and simvastatin regimens in an experimental nephrotic syndrome model. Clin Exp Nephrol. 2008, 12(2):110-8
22) Yilmaz MI, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T, Sonmez A, Cakir E, Oguz Y, Vural A, Yenicesu M, Stenvinkel P, Lindholm B Axelsson J.: Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant. 2008 (23)1621-1627
Eyileten T, CV 6
23) Yilmaz MI, SonmezA, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T, Cakir E, Oguz Y, Vural A, Yenicesu M, Lindholm B, Stenvinkel P, Axelsson J.: ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. J Am Soc Nephrol, 2008(19): 388-395
24) CaglarK, Yilmaz MI, SaglamM, Cakir E, Kilic S, SonmezA, Eyileten T, Yenicesu M, Oguz, Tasar M, Vural A, Ikizler TA, Stenvinkel P, Lindholm B.: Serum Fetuin-A Concentration and Endothelial Dysfunction in Chronic Kidney Disease. Nephron Clin Pract 2008;108:c233-c240
25) Oguz Y, Yilmaz MI, Acikel C, Eyileten T,Caglar K,Oktenli C,Yenicesu M,Vural A.:The relationship between adiponectin levels and degree of proteinuria in patients with nephrotic and non-nephrotic proteinuria. Ren fail.2009,31(1):29-35
26) Yilmaz MI, Axelsson J,Sonmez A,Carrero JJ, Saglam M, Eyileten T,Caglar K,Kirkpantur A , Celik T, Oguz Y,Vural A, Yenicesu M,Lindholm B, Stenvinkel P.: Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria. Clin J Am Soc Nephrol 2009 Mar;4(3):535-541
27) Yilmaz MI, Sonmez A,Saglam M,Gulec M,Kilic S,Eyileten T,Caglar K,Oguz Y,Vural A,Yenicesu M,Zoccali C.: Hemoglobin is inversely related to flow-mediated dilatation in chronic kidney disease. Kidney Int.2009 Jun;75(12):1316-21.
28) Yilmaz MI, Saglam M,Carrero JJ, Qureshi AR, Caglar K,Eyileten T, Sonmez A,Oguz Y,Aslan I,Vural A,Yenicesu M,Stenvinkel P,Lindholm B,Axelsson J.: Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT. A novel marker of endothelial damage? Clin Transplant. 2009 Mar-Apr;23(2):241-
8
29) Afsar B,Elsurer R,Eyileten T,Yilmaz MI, Yenicesu M. Antibody response following hepatitis B Vaccination in dialysis patients: Does depression and life quality matter? Vaccine 2009 Sep 25;27(42):5865-9
30) Sonmez A,Yilmaz MI, Saglam M,Kilic S,Eyileten T,Uckaya G,Caglar K,Oguz Y,Vural A,Yenicesu M,Kutlu M,Kinalp C,Zoccali C.: The relationship between hemoglobin levels and endothelial functions in diabetes mellitus. Clin J Am Soc Nephrol.2010 jan;5(1):45-50
31) Yilmaz MI, Qureshi AR, Carrero JJ, Saglam M, Suliman ME, Caglar K, Eyileten T,Sonmez A,Oguz Y,Vural A,Yenicesu M,Axelsson J.: Predictors of carotid artery intima-media thickness in chronic kidney disease and kidney transplant patients without overt cardiovasculer disease. Am J Nephrol.2010;31(3):214-21
32) Yilmaz MI, Sonmez A,Saglam M,Yaman H,Cayci T,Kilic S,Eyileten T,Caglar K,Oguz Y,Vural A,Yenicesu M,Axellson J.: Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway? Nephrol Dial Transplant.2010(10):3250-6
33) Afsar B,Afsar RE, Sen ST,Kirkpantur A,Eyileten T,Yilmaz MI, Caglar K.: Simple renal cysts and circadian blood pressure: Are they related to each other in patients with hypertension? Int Urol Nephrol.2010 Apr.13
Eyileten T, CV 7
34) Yilmaz MI, Carrero JJ, Martin-Ventura JL, Sonmez A,Saglam M,Celik T,Yaman H,Yenicesu M,Eyileten T,Moreno JA,Egido J,Bianco-Colio LM.: Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: Effects on soluble TWEAK,PTX3 and flow-mediated dilation. Clin J Am Soc Nephrol 2010
Jul;5(7);1174-81
35) Afsar B,Elsurer R,Yilmaz MI, Eyileten T,Yenicesu M.: Irritable bowel syndrome in haemodialysis: Prevalance, link with quality of life and depression. Nephrology(Carlton).2010 Mar;15(2):197-202
36) Eyileten T, Sonmez A, Saglam M, Cakir E, Caglar K, Oguz Y, Vural A,Yenicesu M,Yilmaz MI Effect of renin-angiotensin-aldosterone system(RAAS) blockade on visfatin levels in diabetic nephropathy. Nephrology(Carlton).2010 Mar;15(2):225—9
37) Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Demirkaya E, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Zoccali C.: FGF-23 and vascular dysfunction in patients with stage3 and 4 chronic kidney disease. Kidney int.2010 Oct;78(7):679-85
38) Yilmaz MI, Sonmez A, Karaman M,Ay SA, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Zoccali C.: Low triiodothyronine alters flow-mediated vasodilatation in advanced nondiabetic kidney disease. Am J Nephrol.2011;33(1):25-32
39) Yilmaz MI, Sonmez A, Ortiz A, Saglam M, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Cakar M, Egido J, Altun B, Yenicesu M, Blanco-Colio LM, Carrero JJ. Soluble TWEAK and PTX3 in Nondialysis CKD Patients: Impact on Endothelial Dysfunction and Cardiovascular Outcomes. Clin J Am SocNephrol. 6(4):785-792, (2011).
40) Yilmaz MI, Stenvinkel P, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Cakar M, Altun B, Yenicesu M, Carrero JJ. Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes. Nephrol Dial Transplant. 2011 Nov 26(11):3537-43.
41) Yilmaz MI, Sonmez A, Qureshi AR, Saglam M, Steinvinkel P, Yaman H, Eyileten T,Caglar K, Oguz Y, Taslipinar A, Vural A, Gok M, Unal HU; Yenicesu M, Carrero JJ. Endogenous testosterone
,endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease.
Clin J Am Soc Nephrol. 2011 Jul 6(7):1617-25. Epub 2011 Jun 23
42) Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Mallamaci F,Zoccali C. Comparison of Calcium Acetate and Sevelamer on Vascular Function and Fibroblast Growth Factor 23 in CKD patients A Randomized Clinical Trial. Am J Kidney Dis. 2012;59(2):177-185
43) Kanbay M, Yilmaz MI, Apetrii M, Saglam M, Yaman H, Unal HU, Gok M, Caglar K, Oguz Y, Yenicesu M, Cetinkaya H, Eyileten T, Acıkel C, Vural A, Covic A.: Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients. Am J Nephrol. 2012;36(3):228-37.
Eyileten T, CV 8
44) Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Turker T,Unal HU, Gok M, Cetinkaya H, Eyileten T, Oguz Y, Caglar K, Vural A, Mallamaci F, Zoccali C.: Longitudinal analysis of vascular function and biomarkers of metabolic bone disorders before and after transplantation. Am J Nephrol. 2013;37(2):126-34.
45) Solak Y, Yilmaz MI, Saglam M, Caglar K, Verim S,Unal HU, Gok M, Demirkaya E, gaipov A, Kayrak M, Cetinkaya H, Eyileten T, Turk S, Vural A.: Red cell distribution width is independently related to endothelial dysfunction in patients with chronic kidney disease. Am J Med Sci. 2013 Aug 7.(Epub)
46) Yilmaz MI1, Sonmez A, Saglam M, Yaman H, Unal HU, Gok M, Cetinkaya H, Eyileten T,Oguz Y, Sari S, Yildirim AO, Vural A, Carrero JJ, Blanco-Colio LM. Soluble TWEAK plasma levels increase after renal transplantation and associate with the improvement of endothelial function. Eur J Clin Invest. 2013 Dec;43(12):1250-7. Doi: 10.1111/eci.12166. Epub 2013 Sep 20.
47) Yilmaz MI, Solak Y, Saglam M, Cayci T, Acikel C, Unal HU, Eyileten T, Oguz Y, Sari S, Carrero JJ, Stenvinkel P, Covic A, Kanbay M.: The relationship between IL-10 levels and cardiovascular events in patients with CKD. Clin J Am Soc Nephrol. 2014 Jul;9(7):1207-16. Doi: 10.2215/CJN.08660813. Epub 2014 May 1.
48) Kanbay M, Solak Y, Unal HU, Kurt YG, Gok M, Cetinkaya H, Karaman M, Oguz Y, Eyileten T, Vural A, Covic A, Goldsmith D, Turak O, Yilmaz MI. Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. Int Urol Nephrol. 2014 Aug;46(8):1619-25. Doi: 10.1007/s11255-014-0730-1. Epub 2014 May 23.
49) Yilmaz MI, Demirkaya E, Acikel C, Saldir M, Akar S, Cayci T, Saglam M, Unal HU, Gok M, Polat A, Cetinkaya H, Eyileten T, Sari S, Yildirim AO, Sonmez A, Oguz Y, Vural A, Ozen S, Carrero JJ.: Endothelial function in patients with familial Mediterranean fever-related amyloidosis and association with cardiovascular events. Rheumatology (Oxford). 2014 Nov;53(11):2002-8. Doi: 10.1093/rheumatology/keu231. Epub 2014 Jun 6.
50) Yilmaz MI, Siriopol D, Saglam M, Kurt YG, Unal HU, Eyileten T, Gok M, Cetinkaya H, Oguz Y, Sari S, Vural A, Mititiuc I, Covic A, Kanbay M.: Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int. 2014 Dec;86(6):1213-20. Doi: 10.1038/ki.2014.227. Epub 2014 Jul 2.
51) Kanbay M, Siriopol D, Saglam M, Kurt YG, Gok M, Cetinkaya H, Karaman M, Unal HU, Oguz Y, Sari S, Eyileten T, Goldsmith D, Vural A, Veisa G, Covic A, Yilmaz MI.: Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients.
52) Unal HU, Çelik M, Gökoğlan Y, Çetinkaya H, Gök M, Karaman M, Yilmaz Mİ, Eyileten T, Oğuz Y. Mitral annular calcification and the serum osteocalcin level in patients with chronic kidney disease. Ren Fail. 2014 Nov;36(10):1481-5. Doi: 10.3109/0886022X.2014.962421. Epub 2014 Sep 16.
Eyileten T, CV 9
53) Yilmaz MI, Sonmez A, Saglam M, Kurt YG, Unal HU, Karaman M, Gok M, Cetinkaya H, Eyileten T, Oguz Y, Vural A, Mallamaci F, Zoccali C. Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy. Am J Nephrol. 2014;40(3):208-14. Doi: 10.1159/000366169. Epub 2014 Oct 10.
54) Yilmaz MI, Sonmez A, Saglam M, Cayci T, Kilic S, Unal HU, Karaman M, Cetinkaya H, Eyileten T, Gok M, Oguz Y, Vural A, Mallamaci F, Zoccali C. A longitudinal study of inflammation, CKD- mineral bone disorder, and carotid atherosclerosis after renal transplantation. Clin J Am Soc Nephrol. 2015 Mar 6;10(3):471-9. Doi: 10.2215/CJN.07860814. Epub 2014 Dec 26.
55) Sonmez A, Yilmaz MI, Saglam M, Unal HU, Gok M, Cetinkaya H, Karaman M, Haymana C, Eyileten T, Oguz Y, Vural A, Rizzo M, Toth PP. The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease. Lipids Health Dis. 2015 Apr 16;14:29. Doi: 10.1186/s12944-015-0031-4.
56) Solak Y, Yilmaz MI, Siriopol D, Saglam M, Unal HU, Yaman H, Gok M, Cetinkaya H, Gaipov A, Eyileten T, Sari S, Yildirim AO, Tonbul HZ, Turk S, Covic A, Kanbay M. Serum neutrophil gelatinase-associated lipocalin is associated with cardiovascular events in patients with chronic kidney disease. Int Urol Nephrol. 2015 Dec;47(12):1993-2001. Doi: 10.1007/s11255-015-1136-
4. Epub 2015 Oct 26.
57) Celik T, Yilmaz MI, Balta S, Ozturk C, Unal HU, Aparci M, Karaman M, Demir M, Yildirim AO, Saglam M, Kilic S, Eyileten T, Aydin İ, Iyisoy A. The Relationship Between Plasma Whole Blood Viscosity and Cardiovascular Events in Patients With Chronic Kidney Disease. Clin Appl Thromb Hemost. 2016 Jan 1:1076029616634888. Doi: 10.1177/1076029616634888. [Epub ahead of print]
58) Kanbay M, Afsar B, Siriopol D, Unal HU, Karaman M, Saglam M, Eyileten T, Gezer M, Verim S, Oguz Y, Vural A, Ortiz A, Johnson RJ, Covic A, Yilmaz MI. Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients. Int Urol Nephrol. 2016 Jul;48(7):1129-36. Doi: 10.1007/s11255-016-1271-6. Epub 2016 Mar 23.
59) Yilmaz MI, Siriopol D, Saglam M, Unal HU, Karaman M, Gezer M, Kilinc A, Eyileten T, Guler AK, Aydin İ, Vural A, Oguz Y, Covic A, Ortiz A, Kanbay M. Osteoprotegerin in Chronic Kidney Disease: Associations with Vascular Damage and Cardiovascular Events. Calcif Tissue Int. 2016 Aug;99(2):121-30. Doi: 10.1007/s00223-016-0136-4. Epub 2016 Mar 26.
60) Afsar B, Yilmaz MI, Siriopol D, Unal HU, Saglam M, Karaman M, Gezer M, Sonmez A, Eyileten T, Aydin I, Hamcan S, Oguz Y, Covic A, Kanbay M. Thyroid function and cardiovascular events in chronic kidney disease patients. J Nephrol. 2017 Apr;30(2):235-242. Doi: 10.1007/s40620-016-0300-y. Epub 2016 Apr 2.
61) Kanbay M, Afsar B, Siriopol D, Unal HU, Karaman M, Saglam M, Gezer M, Taş A, Eyileten T, Guler AK, Aydin İ, Oguz Y, Tarim K, Covic A, Yilmaz MI. Endostatin in chronic kidney disease: Associations with inflammation, vascular abnormalities, cardiovascular events and survival. Eur J Intern Med. 2016 Sep;33:81-7. Doi: 10.1016/j. Ejim.2016.06.033. Epub 2016 Jul 7.
Eyileten T, CV 10
62) Haciosmanoglu T, Karacalioglu AO, Eyileten T, Ince S, Arslan N.: A different scintigraphic approach to evaluate the glomerular filtration rate. Rev Esp Med Nucl Imagen Mol. 2017 Mar 28. Pii: S2253-654X(16)30215-3. Doi: 10.1016/j. Remn.2017.01.015. [Epub ahead of print]
63) Gungor O, Unal HU, Guclu A, Gezer M, Eyileten T, Guzel FB, Altunoren O, Erken E, Oguz Y, Kocyigit I, Yilmaz MI.: IL-33 and ST2 levels in chronic kidney disease: Associations with inflammation, vascular abnormalities, cardiovascular events, and survival. PLoS One. 2017 Jun 14;12(6):e0178939. Doi: 10.1371/journal. Pone.0178939. ECollection 2017
64) Eroglu E, Unal HU, Guclu A, Kocyigit I, Karaman M, Saglam M, Gezer M, Tas A, Zararsiz
G, Eyileten T, Aydin İ, Oguz Y, Gungor O, Yilmaz MI.: The association of profilin-1 levels with survival in chronic kidney disease. Eur J Clin Invest. 2017 Dec;47(12). Doi: 10.1111/eci.12839. Epub 2017 Oct 27.
B. CASE REPORTS AND LETTER TO THE EDITOR
1) Y. Oguz, M. Yilmaz, T. Eyileten, K. Caglar, M. Yenicesu, A. Kaya, M. Tasar, M. Saglam, L. Doganci, B. Gulec.: Persistent mediastinal and axillary lymph node tuberculosis in a renal transplant patient with successful outcome. Transplant Proc. 2006 Jun;38(5):1336-40.
2) T. Eyileten, F. Dede, M. Yenicesu, G. Celebi, A. Vural.:Idiopathic tubulointerstitial nephritis and uveitis—‘TINU syndrome’. Nephrol Dial Transplant. 2008 Feb 23(2)
3) Afsar B, Yilmaz MI,Eyileten T.:Do patients with uric acid stones exhibit abnormal circadian blood pressure a hypothesis. Nephrol Dial Transplant., 24(6):2004, (2009).
4) Sengul E, Eyileten T, Ozcan A, Yilmaz MI, Yenicesu M.:Anti-glomerular basement membrane disease with nephrotic proteinuria. Clin Nephrol., 72(2):157-9, (2009).
5) Sengul E, Eyileten T, Ozcan A, Yilmaz MI, Yenıcesu M.:Diffuse alveolar hemorrhage as an unusual presentation of systemic lupus erythematosus. Rheumatol Int., (2009)
